230 related articles for article (PubMed ID: 33093458)
21. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.
Kortmann U; McAlpine JN; Xue H; Guan J; Ha G; Tully S; Shafait S; Lau A; Cranston AN; O'Connor MJ; Huntsman DG; Wang Y; Gilks CB
Clin Cancer Res; 2011 Feb; 17(4):783-91. PubMed ID: 21097693
[TBL] [Abstract][Full Text] [Related]
22. Luteolin exerts a marked antitumor effect in cMet-overexpressing patient-derived tumor xenograft models of gastric cancer.
Lu J; Li G; He K; Jiang W; Xu C; Li Z; Wang H; Wang W; Wang H; Teng X; Teng L
J Transl Med; 2015 Feb; 13():42. PubMed ID: 25638174
[TBL] [Abstract][Full Text] [Related]
23. Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response.
Min A; Jang H; Kim S; Lee KH; Kim DK; Suh KJ; Yang Y; Elvin P; O'Connor MJ; Im SA
Mol Cancer Ther; 2018 Dec; 17(12):2507-2518. PubMed ID: 30232143
[TBL] [Abstract][Full Text] [Related]
24. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
Hijaz M; Chhina J; Mert I; Taylor M; Dar S; Al-Wahab Z; Ali-Fehmi R; Buekers T; Munkarah AR; Rattan R
Gynecol Oncol; 2016 Aug; 142(2):323-31. PubMed ID: 27282964
[TBL] [Abstract][Full Text] [Related]
25. A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin.
Arena S; Corti G; Durinikova E; Montone M; Reilly NM; Russo M; Lorenzato A; Arcella P; Lazzari L; Rospo G; Pagani M; Cancelliere C; Negrino C; Isella C; Bartolini A; Cassingena A; Amatu A; Mauri G; Sartore-Bianchi A; Mittica G; Medico E; Marsoni S; Linnebacher M; Abrignani S; Siena S; Di Nicolantonio F; Bardelli A
Clin Cancer Res; 2020 Mar; 26(6):1372-1384. PubMed ID: 31831554
[TBL] [Abstract][Full Text] [Related]
26. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Sui H; Shi C; Yan Z; Li H
Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
[TBL] [Abstract][Full Text] [Related]
27. Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.
Lin ZP; Zhu YL; Lo YC; Moscarelli J; Xiong A; Korayem Y; Huang PH; Giri S; LoRusso P; Ratner ES
PLoS One; 2018; 13(11):e0207399. PubMed ID: 30444904
[TBL] [Abstract][Full Text] [Related]
28. Effect of a chloride channel inhibitor, 5-nitro-2-(3-phenylpropylamino)-benzoate, on ovarian cancer cell migration.
Yu Z; Zhang ZX; Li S; Gao J
Clin Lab; 2011; 57(7-8):543-50. PubMed ID: 21888019
[TBL] [Abstract][Full Text] [Related]
29. A novel small-molecule PI3K/Akt signaling inhibitor, W934, exhibits potent antitumor efficacy in A549 non-small-cell lung cancer.
Wang J; Wang HY; Shen Y; Liang D; Wang HY; Zhang SQ; Cao YX; Cao L
Anticancer Drugs; 2019 Oct; 30(9):900-908. PubMed ID: 30913062
[TBL] [Abstract][Full Text] [Related]
30. Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression.
Ma X; Dang C; Min W; Diao Y; Hui W; Wang X; Dai Z; Wang X; Kang H
Breast Cancer Res Treat; 2019 Jul; 176(1):109-117. PubMed ID: 30989461
[TBL] [Abstract][Full Text] [Related]
31. PIKfyve-dependent regulation of the Cl- channel ClC-2.
Klaus F; Laufer J; Czarkowski K; Strutz-Seebohm N; Seebohm G; Lang F
Biochem Biophys Res Commun; 2009 Apr; 381(3):407-11. PubMed ID: 19232516
[TBL] [Abstract][Full Text] [Related]
32. MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer.
Yi J; Liu C; Tao Z; Wang M; Jia Y; Sang X; Shen L; Xue Y; Jiang K; Luo F; Liu P; Cheng H
EBioMedicine; 2019 May; 43():225-237. PubMed ID: 30898650
[TBL] [Abstract][Full Text] [Related]
33. Enhanced Anti-Cancer Effect of Folate-Conjugated Olaparib Nanoparticles Combined with Radiotherapy in Cervical Carcinoma.
Li D; Hu C; Yang J; Liao Y; Chen Y; Fu SZ; Wu JB
Int J Nanomedicine; 2020; 15():10045-10058. PubMed ID: 33328733
[TBL] [Abstract][Full Text] [Related]
34. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
35. RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib.
Min A; Im SA; Yoon YK; Song SH; Nam HJ; Hur HS; Kim HP; Lee KH; Han SW; Oh DY; Kim TY; O'Connor MJ; Kim WH; Bang YJ
Mol Cancer Ther; 2013 Jun; 12(6):865-77. PubMed ID: 23512992
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic inhibition of SGK1 suppresses colorectal cancer.
Liang X; Lan C; Jiao G; Fu W; Long X; An Y; Wang K; Zhou J; Chen T; Li Y; Xu J; Huang Q; Xu B; Xiao J
Exp Mol Med; 2017 Nov; 49(11):e399. PubMed ID: 29170478
[TBL] [Abstract][Full Text] [Related]
37. The Ewing Family of Tumors Relies on BCL-2 and BCL-X
Heisey DAR; Lochmann TL; Floros KV; Coon CM; Powell KM; Jacob S; Calbert ML; Ghotra MS; Stein GT; Maves YK; Smith SC; Benes CH; Leverson JD; Souers AJ; Boikos SA; Faber AC
Clin Cancer Res; 2019 Mar; 25(5):1664-1675. PubMed ID: 30348635
[TBL] [Abstract][Full Text] [Related]
38. Preclinical model in HCC: the SGK1 kinase inhibitor SI113 blocks tumor progression in vitro and in vivo and synergizes with radiotherapy.
Talarico C; D'Antona L; Scumaci D; Barone A; Gigliotti F; Fiumara CV; Dattilo V; Gallo E; Visca P; Ortuso F; Abbruzzese C; Botta L; Schenone S; Cuda G; Alcaro S; Bianco C; Lavia P; Paggi MG; Perrotti N; Amato R
Oncotarget; 2015 Nov; 6(35):37511-25. PubMed ID: 26462020
[TBL] [Abstract][Full Text] [Related]
39. Enhancing the sensitivity of ovarian cancer cells to olaparib via microRNA-20b-mediated cyclin D1 targeting.
Zhong Q; Xiong Y; Ling C; Qian Y; Zhao X; Yang H
Exp Biol Med (Maywood); 2021 Jun; 246(11):1297-1306. PubMed ID: 34092127
[TBL] [Abstract][Full Text] [Related]
40. SGK1 mediates the hypotonic protective effect against H
Chen BY; Huang CC; Lv XF; Zheng HQ; Zhang YJ; Sun L; Wang GL; Ma MM; Guan YY
Acta Pharmacol Sin; 2020 Aug; 41(8):1073-1084. PubMed ID: 32139897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
